Corcept Therapeutics | CORT - Sales Revenues


Corcept Therapeutics reported $207.6M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 278.6M 14M Sep/2025
Alaunos Therapeutics USD 2K 2K Mar/2025
ANI Pharmaceuticals USD 227.81M 16.44M Sep/2025
Ardelyx USD 110.33M 12.67M Sep/2025
Aurora Cannabis CAD 90.37M 7.65M Sep/2025
BioMarin Pharmaceutical USD 776M 49M Sep/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Canopy Growth CAD 66.68M 5.45M Sep/2025
Corcept Therapeutics USD 207.6M 13.2M Sep/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
J&J USD 24.6B 610M Dec/2025
Knight Therapeutics CAD 92.26M 3.31M Sep/2024
Merck USD 16.4B 880M Dec/2025
Novartis USD 13.91B 144M Sep/2025
Novartis USD 14.36B 478M Sep/2025
Pacira USD 179.52M 1.58M Sep/2025
Pfizer USD 17.58B 880M Dec/2025
Supernus Pharmaceuticals USD 192.1M 26.6M Sep/2025
TG Therapeutics USD 161.7M 20.6M Sep/2025